DOCSLIB.ORG

Patterns and Predictors of Medication Initiation in Diabetic Peripheral Neuropathy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patterns and Predictors of Medication Initiation in Diabetic Peripheral Neuropathy At a Glance Original Research Original Practical Implications e104 Author Information e119 Web Exclusive www.ajpblive.com Patterns and Predictors of Medication Initiation in Diabetic Peripheral Neuropathy Chris M. Kozma, PhD; Terra L. Slaton, MS; Wing Chow, PharmD, MPH; and Marcia F. T. Rupnow, PhD f the more than 25 million Americans with dia- 1,2 betes, up to 25% will develop painful diabetic ABSTRACT 3,4 O peripheral neuropathy (DPN). Patients with DPN Objectives: To investigate patterns and predictors of medication are generally in poorer health and incur higher healthcare initiation and type of medication initiated in patients with newly resource utilization and costs than similar patients without diagnosed diabetic peripheral neuropathy (DPN). DPN.5 Moreover, these patients are more likely to have Study Design: Retrospective analysis of a nationwide administra- greater numbers of comorbidities including musculoskeletal tive claims database. and other neuropathic pain–related conditions,6,7 increasing Methods: Adults with a new principal DPN diagnosis were categorized as initially untreated if they had no newly initiated DPN- the likelihood that they will be prescribed pain medications. related medication within the fi rst 14 days after diagnosis. Bivariate Given the clinical and economic burden associated with logistic regression evaluated predictors for newly initiating medica- painful DPN, deeper understanding of factors that lead to tion versus being initially untreated. Multinomial logistic regression medication initiation and medication choice is necessary for evaluated predictors for each medication category (antidepres- optimization of patient outcomes. sants, anticonvulsants, or multiple medications versus opioids). Painful DPN is a challenging chronic condition to man- Results: Of 53,753 patients with DPN, 46,335 (86%) were age and often requires a multimodal approach, in parallel initially untreated and 7418 (14%) newly initiated an anticon- vulsant (48%), opioid (28%), antidepressant (18%), or multiple or sequentially. Guidelines recommend antidepressants or medications (6%). Having a preindex claim for an anticonvulsant, anticonvulsants as fi rst-line treatments in the management of antidepressant, or weak opioid predicted newly initiating another painful DPN.8-10 Of the antidepressants and anticonvulsants DPN-related medication. A weak opioid preindex predicted switch- available in the United States, only duloxetine (an antide- ing to another medication category after diagnosis and a strong pressant) and pregabalin (an anticonvulsant) are indicated opioid preindex predicted switching to an antidepressant or multiple medications. A preindex anticonvulsant predicted switch- for the management of painful DPN.11,12 However, a meta- ing to an opioid. A preindex antidepressant was not predictive of analysis of the available data suggested that other antidepres- switching. Of the patients who newly initiated medication, 28% had sants (tricyclic antidepressants, selective serotonin reuptake received an opioid preindex and 43% to 74% received an opioid inhibitors) and anticonvulsants (gabapentin, sodium-channel between 14 and 180 days postindex. blockers, membrane-stabilizing agents) also reduce chronic Conclusions: Prior medication use is the most signifi cant predic- neuropathic pain more effectively than placebo.13 tor of whether patients initiate a new medication at the time of When antidepressants or anticonvulsants provide insuf- a new DPN diagnosis, as well as what type of medication they receive. Opioid use is common before and after starting a new fi cient pain relief, guidelines for the management of pain- medication for DPN. ful DPN recommend opioid therapy.8-10 Limited literature Am J Pharm Benefi ts. 2013;5(5):e111-e121 examining treatment patterns within patients with painful DPN has suggested that opioids are a commonly used class of medications,7,13 but the reasons and timing for introduc- ing an opioid regimen are not well documented. Given the chronic nature of DPN, treatment with a long-acting opioid (sustained-release, extended-release, or controlled-release formulations) is a recommended component of multimodal management strategies.14 Currently, only 1 opioid is indicated www.ajpblive.com Vol. 5, No. 5 • The American Journal of Pharmacy Benefi ts e111 I Kozma • Slaton • Chow • Rupnow The index date was the date of the fi rst principal PRACTICAL IMPLICATIONS diagnosis of DPN in the identifi cation window Improved understanding of pain progression and consideration of what constitutes (January 1, 2006, to June 30, 2009), which was optimal pain management are needed in planning for diabetic peripheral neuropathy selected to allow for analysis of claims data for (DPN) medication pharmacy benefi ts. 360 days preindex through 180 days postindex. I At DPN diagnosis, 14% of patients initiated a DPN-related medication, mostly an To be eligible for inclusion, patients were re- anticonvulsant or antidepressant (66%), followed by opioids (28%) and combina- quired to be at least 18 years of age at the in- tion treatment (6%). dex date and continuously eligible for insurance I Having a DPN-related medication claim before DPN diagnosis predicted initiating plan and pharmacy coverage throughout their another DPN-related medication at diagnosis, illustrating the diffi culties in fi nding optimal regimens. preindex and postindex periods. Patients were excluded if they had a diagnosis of DPN in the I Many patients received opioids before or after their diagnosis. 360-day preindex period (ie, only “newly” diag- nosed patients were analyzed). Patients were divided into 2 cohorts: the new- ly initiated medication group and the initially un- for the management of painful DPN in the United States treated group. Because prescriptions were not linked to a (tapentadol extended release).15 Nonetheless, patients specifi c diagnosis, rules were defi ned to identify patients with DPN are up to 10 times more likely to receive a who received medications for the DPN diagnoses. The short-acting opioid than a long-acting opioid.2,7,16-20 To goal of the rules was to create a high degree of confi dence our knowledge, predictors for the use of long-acting or that the new medication therapy was related to the DPN short-acting opioids in the management of painful DPN diagnosis. The newly initiated medication group included have not been explored previously. patients who received a new prescription for a DPN-re- The primary objective of this analysis was to investi- lated medication (Appendix) within 14 days postindex. gate predictors of medication initiation and type of medi- The 14-day window was selected to identify medications cation initiated in newly diagnosed DPN patients. that were likely to have been initiated for the new DPN diagnosis; it was long enough to allow patients up to 2 METHODS weeks to fi ll their new prescription after the DPN diagno- Data Source sis, but short enough to exclude DPN-related medications The data source for this analysis was employer-based that were prescribed for subsequent diagnoses. Patients claims from the MarketScan Research Database.21 The an- in the newly initiated medication group could have used nual medical databases include private-sector health data other medications (including another medication from the from approximately 100 payers and more than 500 million same category) previously, but they were excluded from claim records. The database represents the medical experi- the analysis if they had another claim in the 360-day pre- ence of insured employees and their dependents for active index period for the same medication (eg, generic level) employees, early retirees, those who continue on COBRA, that they received within 14 days postindex. and Medicare-eligible retirees with employer-provided To increase certainty that patients were using medica- Medicare Supplemental plans. The database includes in- tions related to DPN and not for other purposes, patients tegrated patient-level data for inpatient, outpatient, and in the newly initiated medication group were excluded drug claims, as well as insurance eligibility. The database from the analysis if they had any of the following diagno- is de-identifi ed and compliant with the Health Insurance ses between the DPN diagnosis and the newly initiated Portability and Accountability Act of 1996. As such, no in- medication: a newly initiated antidepressant and a men- stitutional review board approval was necessary. tal health diagnosis (ICD-9-CM codes 290.xx-319.xx); a newly initiated anticonvulsant and a diagnosis of epilepsy Study Design and recurrent seizures or convulsions (ICD-9-CM codes This retrospective analysis included claims from Janu- 345.xx or 780.3); a newly initiated antidementia agent ary 1, 2005, through December 31, 2009 (Figure 1). A and a diagnosis of a mental disorder or disease of the diagnosis of DPN was identifi ed from International Clas- nervous and sense organs (ICD-9-CM codes 290.xx-319. sifi cation of Diseases, 9th Revision, Clinical Modifi cation xx or 320.xx-389.xx); or a newly initiated antihyperten- (ICD-9-CM) codes 250.6X (diabetes with neurologic sive or antiarrhythmic agent and disease of the circulatory manifestations) or 357.2X (polyneuropathy in diabetes). system (ICD-9-CM codes 309.xx-459.xx). e112 The American Journal of Pharmacy Benefi ts • September/October 2013 www.ajpblive.com Patterns and Predictors of Medication Figure 1. Study Timeline ID window starts ID window ends 1/1/2006 6/30/2009 New Rx
Load more

Recommended publications
  • Neuropathy, Radiculopathy & Myelopathy
    Neuropathy, Radiculopathy & Myelopathy Jean D. Francois, MD Neurology & Neurophysiology Purpose and Objectives PURPOSE Avoid Confusing Certain Key Neurologic Concepts OBJECTIVES • Objective 1: Define & Identify certain types of Neuropathies • Objective 2: Define & Identify Radiculopathy & its causes • Objective 3: Define & Identify Myelopathy FINANCIAL NONE DISCLOSURE Basics What is Neuropathy? • The term 'neuropathy' is used to describe a problem with the nerves, usually the 'peripheral nerves' as opposed to the 'central nervous system' (the brain and spinal cord). It refers to Peripheral neuropathy • It covers a wide area and many nerves, but the problem it causes depends on the type of nerves that are affected: • Sensory nerves (the nerves that control sensation>skin) causing cause tingling, pain, numbness, or weakness in the feet and hands • Motor nerves (the nerves that allow power and movement>muscles) causing weakness in the feet and hands • Autonomic nerves (the nerves that control the systems of the body eg gut, bladder>internal organs) causing changes in the heart rate and blood pressure or sweating • It May produce Numbness, tingling,(loss of sensation) along with weakness. It can also cause pain. • It can affect a single nerve (mononeuropathy) or multiple nerves (polyneuropathy) Neuropathy • Symptoms usually start in the longest nerves in the body: Feet & later on the hands (“Stocking-glove” pattern) • Symptoms usually spread slowly and evenly up the legs and arms. Other body parts may also be affected. • Peripheral Neuropathy can affect people of any age. But mostly people over age 55 • CAUSES: Neuropathy has a variety of forms and causes. (an injury systemic illness, an infection, an inherited disorder) some of the causes are still unknown.
    [Show full text]
  • Hereditary Spastic Paraparesis: a Review of New Developments
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.69.2.150 on 1 August 2000. Downloaded from 150 J Neurol Neurosurg Psychiatry 2000;69:150–160 REVIEW Hereditary spastic paraparesis: a review of new developments CJ McDermott, K White, K Bushby, PJ Shaw Hereditary spastic paraparesis (HSP) or the reditary spastic paraparesis will no doubt Strümpell-Lorrain syndrome is the name given provide a more useful and relevant classifi- to a heterogeneous group of inherited disorders cation. in which the main clinical feature is progressive lower limb spasticity. Before the advent of Epidemiology molecular genetic studies into these disorders, The prevalence of HSP varies in diVerent several classifications had been proposed, studies. Such variation is probably due to a based on the mode of inheritance, the age of combination of diVering diagnostic criteria, onset of symptoms, and the presence or other- variable epidemiological methodology, and wise of additional clinical features. Families geographical factors. Some studies in which with autosomal dominant, autosomal recessive, similar criteria and methods were employed and X-linked inheritance have been described. found the prevalance of HSP/100 000 to be 2.7 in Molise Italy, 4.3 in Valle d’Aosta Italy, and 10–12 Historical aspects 2.0 in Portugal. These studies employed the In 1880 Strümpell published what is consid- diagnostic criteria suggested by Harding and ered to be the first clear description of HSP.He utilised all health institutions and various reported a family in which two brothers were health care professionals in ascertaining cases aVected by spastic paraplegia. The father was from the specific region.
    [Show full text]
  • Diabetic Neuropathy
    6 Diabetic Neuropathy Solomon Tesfaye, MD, FRCP INTRODUCTION Polyneuropathy is one of the commonest complications of the diabetes and the com- monest form of neuropathy in the developed world. Diabetic polyneuropathy encompasses several neuropathic syndromes, the most common of which is distal symmetrical neuropa- thy, the main initiating factor for foot ulceration. The epidemiology of diabetic neuropathy has recently been reviewed in reasonable detail (1). Several clinic- (2,3) and population- based studies (4,5) show surprisingly similar prevalence rates for distal symmetrical neu- ropathy, affecting about 30% of all people with diabetes. The EURODIAB prospective complications study, which involved the examination of 3250 patient with type 1 from 16 European countries, found a prevalence rate of 28% for distal symmetrical neuropathy (2). After excluding those with neuropathy at baseline, the study showed that over a 7-year period, about one-quarter of patients with type 1 diabetes developed distal symmetrical neuropathy; age, duration of diabetes, and poor glycemic control being major determinants (6). The development of neuropathy was also associated with potentially modifiable car- diovascular risk factors such as serum lipids, hypertension, body mass index, and cigaret smoking (6). Furthermore, cardiovascular disease at baseline carried a twofold risk of neu- ropathy, independent of cardiovascular risk factors (6). Based on recent epidemiological studies, correlates of diabetic neuropathy include increasing age, increasing duration of dia- betes, poor glycemic control, retinopathy, albuminuria, and vascular risk factors (1,2,4,6). The differing clinical presentation of the several neuropathic syndromes in diabetes sug- gests varied etiological factors. CLASSIFICATION Clinical classification of the various syndromes of diabetic peripheral neuropathy has proved difficult.
    [Show full text]
  • Hereditary Spastic Paraplegia
    8 Hereditary Spastic Paraplegia Notes and questions Hereditary Spastic Paraplegia What is Hereditary Spastic Paraplegia? Hereditary Spastic Paraplegia (HSP) is a medical term for a condition that affects muscle function. The terms spastic and paraplegia comes from several words in Greek: • ‘spastic’ means afflicted with spasms (an alteration in muscle tone that results in affected movements) • ‘paraplegia’ meaning an impairment in motor or sensory function of the lower extremities (from the hips down) What are the signs and symptoms of HSP? Muscular spasticity • Individuals with HSP commonly will have lower extremity weakness, spasticity, and muscle stiffness. • This can cause difficulty with walking or a “scissoring” gait. We are grateful to an anonymous donor for making a kind and Other common signs or symptoms include: generous donation to the Neuromuscular and Neurometabolic Centre. • urinary urgency • overactive or over responsive “brisk” reflexes © Hamilton Health Sciences, 2019 PD 9983 – 01/2019 Dpc/pted/HereditarySpasticParaplegia-trh.docx dt/January 15, 2019 ____________________________________________________________________________ 2 7 Hereditary Spastic Paraplegia Hereditary Spastic Paraplegia HSP is usually a chronic or life-long disease that affects If you have any questions about DM1, please speak with your people in different ways. doctor, genetic counsellor, or nurse at the Neuromuscular and Neurometabolic Centre. HSP can be classified as either “Uncomplicated HSP” or “Complicated HSP”. Notes and questions Types of Hereditary Spastic Paraplegia 1. Uncomplicated HSP: • Individuals often experience difficulty walking as the first symptom. • Onset of symptoms can begin at any age, from early childhood through late adulthood. • Symptoms may be non-progressive, or they may worsen slowly over many years.
    [Show full text]
  • Peripheral Neuropathy
    Peripheral Neuropathy U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health Peripheral Neuropathy What is peripheral neuropathy? n estimated 20 million people in A the United States have some form of peripheral neuropathy, a condition that develops as a result of damage to the peripheral nervous system — the vast communications network that transmits information between the central nervous system (the brain and spinal cord) and every other part of the body. (Neuropathy means nerve disease or damage.) Symptoms can range from numbness or tingling, to pricking sensations (paresthesia), or muscle weakness. Areas of the body may become abnormally sensitive leading to an exaggeratedly intense or distorted experience of touch (allodynia). In such cases, pain may occur in response to a stimulus that does not normally provoke pain. Severe symptoms may include burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Damage to nerves that supply internal organs may impair digestion, sweating, sexual function, and urination. In the most extreme cases, breathing may become difficult, or organ failure may occur. Peripheral nerves send sensory information back to the brain and spinal cord, such as a message that the feet are cold. Peripheral 1 nerves also carry signals from the brain and spinal cord to the muscles to generate movement. Damage to the peripheral nervous system interferes with these vital connections. Like static on a telephone line, peripheral neuropathy distorts and sometimes interrupts messages between the brain and spinal cord and the rest of the body. Peripheral neuropathies can present in a variety of forms and follow different patterns.
    [Show full text]
  • Diabetic Peripheral Neuropathy
    PHYSICIAN REFERRAL DIABETIC PATIENT’S NAME: PERIPHERAL _________________________________ _________________________________ NEUROPATHY DIAGNOSIS: _________________________________ _________________________________ PRECAUTIONS: BACCI & GLINN _________________________________ PHYSICAL THERAPY, INC. _________________________________ For more information on this and _____ Evaluate and Treat other topics, visit our website at: “Therapy with a Difference” _____ Exercise Program (i.e. home, gym) www.bandgpt.com _____ Functional Conditioning _____ Therapeutic Exercise _____ Balance Training _____ Aquatic Therapy (Hanford only) BACCI & GLINN _____ Modalities PHYSICAL THERAPY, INC. _____ Other ______________________ COMMENTS: _____________________ 5533 West Hillsdale Avenue, Suite A Visalia, CA 93291 ________________________________ Phone: 559-733-2478 Frequency: ___ x per week for ___ weeks Fax: 559-733-2470 Signature: _________________________ 331 North 11th Avenue (Physician signature) Hanford, CA 93230 Date: __________ Phone: 559-582-1027 Fax: 559-582-8105 SAME DAY APPOINTMENTS AVAILABLE Referrals are accepted from any physician. A physician’s order and diagnosis are required for evaluation and treatment. We accept most insurances including Medicare. Johnson Designs Bacci & Glinn Physical Therapy, Inc. Hanford: 559-582-1027 Visalia: 559-733-2478 Diabetic Peripheral Neuropathy What is Diabetic Signs and Symptoms of Treatment Options Peripheral Neuropathy? Diabetic Peripheral Neuropathy There is no cure for diabetic neuropa- Diabetic neuropathy is a nerve ♦ Tingling, tightness, or burning, shooting thy. Treatment focuses on slowing the disorder commonly caused by or stabbing pain in feet, hands, or other progression of the disease. Your diabetes. High blood sugar levels parts of the body. physician will determine the best from diabetes can damage nerves ♦ Reduced feeling or numbness, most treatment for your peripheral neuropa- throughout the body. About 50% of often in the feet.
    [Show full text]
  • Diabetic Neuropathy
    PRIMER Diabetic neuropathy Eva L. Feldman1*, Brian C. Callaghan1, Rodica Pop-Busui2, Douglas W. Zochodne3, Douglas E. Wright4, David L. Bennett5, Vera Bril6,7, James W. Russell8 and Vijay Viswanathan9 Abstract | The global epidemic of prediabetes and diabetes has led to a corresponding epidemic of complications of these disorders. The most prevalent complication is neuropathy , of which distal symmetric polyneuropathy (for the purpose of this Primer, referred to as diabetic neuropathy) is very common. Diabetic neuropathy is a loss of sensory function beginning distally in the lower extremities that is also characterized by pain and substantial morbidity. Over time, at least 50% of individuals with diabetes develop diabetic neuropathy. Glucose control effectively halts the progression of diabetic neuropathy in patients with type 1 diabetes mellitus, but the effects are more modest in those with type 2 diabetes mellitus. These findings have led to new efforts to understand the aetiology of diabetic neuropathy , along with new 2017 recommendations on approaches to prevent and treat this disorder that are specific for each type of diabetes. In parallel, new guidelines for the treatment of painful diabetic neuropathy using distinct classes of drugs, with an emphasis on avoiding opioid use, have been issued. Although our understanding of the complexities of diabetic neuropathy has substantially evolved over the past decade, the distinct mechanisms underlying neuropathy in type 1 and type 2 diabetes remains unknown. Future discoveries on disease pathogenesis will be crucial to successfully address all aspects of diabetic neuropathy , from prevention to treatment. The International Diabetes Federation estimates that neuropathies secondary to diabetes can occur (Fig.
    [Show full text]
  • Diabetic Neuropathy: a Position Statement by the American
    136 Diabetes Care Volume 40, January 2017 Diabetic Neuropathy: A Position Rodica Pop-Busui,1 Andrew J.M. Boulton,2 Eva L. Feldman,3 Vera Bril,4 Roy Freeman,5 Statement by the American Rayaz A. Malik,6 Jay M. Sosenko,7 and Dan Ziegler8 Diabetes Association Diabetes Care 2017;40:136–154 | DOI: 10.2337/dc16-2042 Diabetic neuropathies are the most prevalent chronic complications of diabetes. This heterogeneous group of conditions affects different parts of the nervous system and presents with diverse clinical manifestations. The early recognition and appropriate man- agement of neuropathy in the patient with diabetes is important for a number of reasons: 1. Diabetic neuropathy is a diagnosis of exclusion. Nondiabetic neuropathies may be present in patients with diabetes and may be treatable by specific measures. 2. A number of treatment options exist for symptomatic diabetic neuropathy. 3. Up to 50% of diabetic peripheral neuropathies may be asymptomatic. If not recognized and if preventive foot care is not implemented, patients are at risk for injuries to their insensate feet. 4. Recognition and treatment of autonomic neuropathy may improve symptoms, POSITION STATEMENT reduce sequelae, and improve quality of life. Among the various forms of diabetic neuropathy, distal symmetric polyneurop- athy (DSPN) and diabetic autonomic neuropathies, particularly cardiovascular au- tonomic neuropathy (CAN), are by far the most studied (1–4). There are several 1 atypical forms of diabetic neuropathy as well (1–4). Patients with prediabetes may Division of Metabolism, Endocrinology & Diabe- – tes, Department of Internal Medicine, University also develop neuropathies that are similar to diabetic neuropathies (5 10).
    [Show full text]
  • Nerve Pain in Diabetes
    Information O from Your Family Doctor Nerve Pain in Diabetes What is nerve pain in diabetes? feeling in your feet and it affects your balance, Nerve pain with diabetes is called neuropathy there are special shoes that can help. (new-ROP-uh-thee). It is common in people with uncontrolled diabetes. It usually starts in What can I expect? the feet and may go up the legs. It may cause Medicine will lessen the pain for many patients, burning pain or a loss of feeling. but most will still have some pain. It is also important to wear proper fitting shoes. And, What causes it? every time you see the doctor, have the doctor Nerves are like wires that bring feeling to your check your feet for injuries you cannot feel. brain from other parts of the body. High blood sugar levels can damage those nerves. The Where can I get more information? longer you have high blood sugar, the more Your doctor likely you are to get nerve damage. The nerves AAFP’s Patient Education Resource in your feet are usually the first to be damaged. http://familydoctor.org/familydoctor/en/diseases- Nerves in other parts of the body can be conditions/diabetic-neuropathy.html damaged, too. American Diabetes Association http://www.diabetes.org/living-with-diabetes/ How do I know if I have it? complications/neuropathy/peripheral-neuropathy.html If you have nerve damage in your feet, you will National Institutes of Health and National Institute of notice pain or loss of feeling. Your doctor can Diabetes and Digestive and Kidney Diseases do tests to be sure that is what is causing the http://www.niddk.nih.gov/health-information/health- problem.
    [Show full text]
  • General Approach to Peripheral Nerve Disorders
    Review Article Address correspondence to Dr James A. Russell, General Approach to Lahey Hospital and Medical Center, Department of Neurology, 41 Mall Rd, Peripheral Nerve Burlington, MA 01805, [email protected]. Relationship Disclosure: Disorders Dr Russell has served as a consultant for W2O Group, receives publishing royalties James A. Russell, DO, FAAN from McGraw-Hill Education, and has received personal compensation for medicolegal ABSTRACT record review. Unlabeled Use of Purpose of Review: This article provides a conceptual framework for the Products/Investigational evaluation of patients with suspected polyneuropathy to enhance the clinician’s Use Disclosure: ability to localize and confirm peripheral nervous system pathology and, when Dr Russell reports no disclosure. possible, identify an etiologic diagnosis through use of rational clinical and judicious * 2017 American Academy testing strategies. of Neurology. Recent Findings: Although these strategies are largely time-honored, recent insights pertaining to the pathophysiology of certain immune-mediated neuropa- thies and to evolving genetic testing strategies may modify the way that select causes of neuropathy are conceptualized, evaluated, and managed. Summary: The strategies suggested in this article are intended to facilitate accurate bedside diagnosis in patients with suspected polyneuropathy and allow efficient and judicious use of supplementary testing and application of rational treatment when indicated. Continuum (Minneap Minn) 2017;23(5):1241–1262. INTRODUCTION
    [Show full text]
  • Small Fiber Neuropathy in Patients Meeting Diagnostic Criteria For
    olog eur ica N l D f i o s l o a r n d r e u r s o J Levine, et al., J Neurol Disord 2016, 4:7 Journal of Neurological Disorders DOI: 10.4172/2329-6895.1000305 ISSN: 2329-6895 Research Article Open Access Small Fiber Neuropathy in Patients Meeting Diagnostic Criteria for Fibromyalgia Todd D Levine1*, David S Saperstein1, Aidan Levine1, Kevin Hackshaw2 and Victoria Lawson2 1Phoenix Neurological Associates, 5090 N, 40th Street, Suite 250, Phoenix, AZ 85018, USA 2Division of Neuromuscular Diseases, Department of Neurology, The Ohio State Wexner Medical Center, 395 W. 12th Ave, 7th Floor, Columbus, OH 43210, USA *Corresponding author: Todd D Levine, Phoenix Neurological Associates, LTD. 5090 N 40th Street, Suite # 250, Phoenix, AZ 85018, USA, Tel: 6022583354; Fax: 6022583368; E-mail: [email protected] Rec date: Sep 21, 2016; Acc date: Oct 06, 2016; Pub date: Oct 11, 2016 Copyright: © 2016 Levine TD. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Abstract Introduction: The cause for fibromyalgia (FM) is unknown and diagnostic criteria can be nonspecific. Many patients with FM have nonspecific sensory symptoms consistent with a neuropathic process. Previous studies have shown that a significant percentage of patients diagnosed with FM have small fiber neuropathy (SFN) based on decreased intraepidermal nerve fiber density (IENFD) on according to punch skin biopsy testing. The purpose of this study was to demonstrate that punch skin biopsy testing is an effective way to identify SFN and its underlying causes in patients previously diagnosed with FM.
    [Show full text]
  • Pharmacologic Management of Chronic Neuropathic Pain Review of the Canadian Pain Society Consensus Statement
    Clinical Review Pharmacologic management of chronic neuropathic pain Review of the Canadian Pain Society consensus statement Alex Mu MD FRCPC Erica Weinberg MD Dwight E. Moulin MD PhD Hance Clarke MD PhD FRCPC Abstract Objective To provide family physicians with EDITOR’S KEY POINTS a practical clinical summary of the Canadian • Gabapentinoids and tricyclic antidepressants play an important role in Pain Society (CPS) revised consensus first-line management of neuropathic pain (NeP). Evidence published statement on the pharmacologic management since the 2007 Canadian Pain Society consensus statement on treatment of neuropathic pain. of NeP shows that serotonin-norepinephrine reuptake inhibitors should now also be among the first-line agents. Quality of evidence A multidisciplinary • Tramadol and opioids are considered second-line treatments owing to their interest group within the CPS conducted a increased complexity of follow-up and monitoring, plus their potential for systematic review of the literature on the adverse side effects, medical complications, and abuse. Cannabinoids are current treatments of neuropathic pain in currently recommended as third-line agents, as sufficient-quality studies are drafting the revised consensus statement. currently lacking. Recommended fourth-line treatments include methadone, anticonvulsants with lesser evidence of efficacy (eg, lamotrigine, lacosamide), tapentadol, and botulinum toxin. There is some support for analgesic Main message Gabapentinoids, tricyclic combinations in selected NeP conditions. antidepressants, and serotonin-norepinephrine reuptake inhibitors are the first-line agents • Many of these pharmacologic treatments are off-label for pain or for treating neuropathic pain. Tramadol and on-label for specific pain conditions, and these issues should be clearly other opioids are recommended as second- conveyed and documented.
    [Show full text]